Please assess the completion status of the following clinical trial:

Trial Title: Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must present with non-Hodgkins Lymphoma (Low, Intermediate or High Grade) or Hodgkins Disease, CLL or Multiple Myeloma~* Life expectancy \> 6 months with Karnofsky Performance Index of \> =70~* Evaluable lesion as objective indicator of response~* Scheduled for at least one myelosuppressive cytotoxic regimen (experimental chemotherapy allowed) for at least 4-6 months~* Patients with reproductive potential must have used an adequate contraceptive method~* Transferrin saturation = 20% and serum ferritin = 50 ng/mL Bone marrow evaluations may be performed to determine if iron stores are adequate~* histologic documentation of disease.~Exclusion Criteria:~* Patients with no second active malignancy or history of other malignancy diagnosed within preceding 5 years (other than basal cell carcinoma or cervical cancer)~* No uncontrolled hypertension~* active, unresolved infection~* anemia due to factors other than cancer/chemotherapy, i.e., iron, folate, hemolysis, or GI bleeding~* Receiving Epoetin alfa independent of protocol~* Received chemotherapy with the previous 14 days~* Prior total lymphoid, extensive abdominal or inverted Y radiation therapy~* No use of interferons or interleukins during study~* No use of nonchemotherapy experimental agents within preceding 30 days~* No Hodgkins Disease patients who are chemotherapy naïve~* Received stem cell transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).